• Prescribing Information
  • Patient Information
  • Patient Site
  • Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    EUCRISA Safety Data

    Safety profile established in 4 studies, including pivotal and open-label safety extension studies, and an open-label infant safety study

    EUCRISA study design for Open-Label Safety Extension study1,2

    OPEN-LABEL SAFETY EXTENSION STUDY2,4

    Eligible patients who completed Pivotal Trial 1 and Pivotal Trial 2 were enrolled in the open-label safety extension study.2
    517 patients were cycled on or off therapy in 4-week intervals per study protocol for 48 weeks. Adverse events, serious adverse events, clinical laboratory results, local tolerability, vital signs and physical examinations were evaluated.
    ​​​​​​​The open-label extension study did not evaluate the efficacy in EUCRISA

    Open-Label Safety Extension (AD-303)4

    Participants in Trials 1 and 2 were given the option of participating in a long-term, open-label, single-arm safety study for 48 weeks; patients from both the EUCRISA and Emollient-rich Vehicle arms of the pivotal trials were eligible to participate

    Open-Label Safety Extension Primary Endpoints

    • Adverse events and serious adverse events
    • Changes in disease severity, including the concomitant use of TCS or TCI rescue medications3


        *Patients could use non-medicated emollients as needed in an off-treatment period.
    246 patients were discontinued in the open-label safety extension study. Reasons for discontinuation were: sponsor closure of the study (109), withdrawal by parent or guardian (63), lost to follow-up (36), withdrawal by patient (23), adverse event (9), other (6), death (0).4
    ISGA=Investigator’s Static Global Assessment; TCS=topical corticosteroid; TCI=topical calcineurin inhibitor.

    Eligible patients who completed Pivotal Trial 1 and Pivotal Trial 2 were enrolled in the open-label safety extension study.2
    517 patients were cycled on or off therapy in 4-week intervals per study protocol for 48 weeks. Adverse events, serious adverse events, clinical laboratory results, local tolerability, vital signs and physical examinations were evaluated.
    ​​​​​​​The open-label extension study did not evaluate the efficacy in EUCRISA

    Open-Label Safety Extension (AD-303)4

    Participants in Trials 1 and 2 were given the option of participating in a long-term, open-label, single-arm safety study for 48 weeks; patients from both the EUCRISA and Emollient-rich Vehicle arms of the pivotal trials were eligible to participate

    Open-Label Safety Extension Primary Endpoints

    • Adverse events and serious adverse events
    • Changes in disease severity, including the concomitant use of TCS or TCI rescue medications3

      ​​​​​​​

        * Patients could use non-medicated emollients as needed in an off-treatment period.
    ​​​​​​​246 patients were discontinued in the open-label safety extension study. Reasons for discontinuation were: sponsor closure of the study (109), withdrawal by parent or guardian (63), lost to follow-up (36), withdrawal by patient (23), adverse event (9), other (6), death (0).4
    ISGA=Investigator’s Static Global Assessment; TCS=topical corticosteroid; TCI=topical calcineurin inhibitor.

        *Trial 1 and Trial 2.
    This study reflects information from the pivotal trials where patients enrolled were 2 years and older.

    References
    1. EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
    2. Data on File. Pfizer Inc., New York, NY.
    3. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
    4. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641-649.e5.

    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
    ​​​​​​​
    Not an actual patient

    Watch JP's story

    ** This is an optional area where footnotes can live.

    Rescue Therapy Endpoint

    Read about rescue therapy in the 48 week Open-Label Safety Extension study

    Learn more

    ** This is an optional area where footnotes can live.

    Exploratory Pruritus Endpoint

    Find out more about the time to relief in pruritus as found in the Phase III study's exploratory endpoint

    Learn more

    ** This is an optional area where footnotes can live.

    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    ** This is an optional area where footnotes can live.

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.